Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration.

Giannakaki-Zimmermann, Helena; Ebneter, Andreas; Munk, Marion; Wolf, Sebastian; Zinkernagel, Martin (2016). Outcomes when Switching from a pro re nata Regimen to a Treat and Extend Regimen Using Aflibercept in Neovascular Age-Related Macular Degeneration. Ophthalmologica, 236(4), pp. 201-206. Karger 10.1159/000452929

[img]
Preview
Text
452929.pdf - Published Version
Available under License Publisher holds Copyright.

Download (219kB) | Preview

PURPOSE To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. PROCEDURE Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed. RESULTS Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively). CONCLUSION A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology

UniBE Contributor:

Ebneter, Andreas; Munk, Marion and Zinkernagel, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0030-3755

Publisher:

Karger

Language:

English

Submitter:

Andreas Ebneter

Date Deposited:

09 Jan 2017 15:02

Last Modified:

03 Dec 2017 02:30

Publisher DOI:

10.1159/000452929

PubMed ID:

27907924

BORIS DOI:

10.7892/boris.91039

URI:

https://boris.unibe.ch/id/eprint/91039

Actions (login required)

Edit item Edit item
Provide Feedback